<DOC>
	<DOCNO>NCT01789736</DOCNO>
	<brief_summary>In double-masked , randomize , multi-center , active-controlled parallel study , patient randomize receive either fixed dose combination AR-12286 travoprost , AR-12286 , travoprost . The hypothesis difference treatment arm .</brief_summary>
	<brief_title>A Study Assessing PG286 Ophthalmic Solution , 0.5 % Compared Its Individual Components 28 Days</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Subject inclusion criterion 1 . 18 year age great . 2 . Diagnosis open angle glaucoma ( OAG ) ocular hypertension ( OHT ) . 3 . Unmedicated ( postwashout ) IOP ≥ 22 mm Hg 2 qualification visit ( 08:00 hr ) , 27 day apart . At second qualification visit , IOP &gt; 21 mmHg 10:00 16:00 hr . 4 . Corrected visual acuity eye +1.0 logMAR good ETDRS eye ( equivalent 20/200 ) . 5 . Able willing give sign informed consent follow study instruction . Subject exclusion criterion Excluded study individual follow characteristic : Ophthalmic ( either eye ) : 1 . Glaucoma : pseudoexfoliation pigment dispersion component , history angle closure , narrow angle . Note : Previous laser peripheral iridotomy NOT acceptable . 2 . Intraocular pressure &gt; 35 mm Hg , use two ocular hypotensive medication within 30 day screen . Note : fix dose combination count two medication . 3 . Known hypersensitivity component formulation ( benzalkonium chloride , zinc , etc . ) , travoprost , topical anesthetic . 4 . Previous glaucoma intraocular surgery glaucoma laser procedure study eye ( ) . 5 . Refractive surgery study eye ( ) ( e.g. , radial keratotomy , PRK , LASIK , etc. ) . 6 . Ocular trauma within six month prior screen , ocular surgery laser treatment within three month prior screen . 7 . Evidence ocular infection , inflammation , clinically significant blepharitis , conjunctivitis , history herpes simplex keratitis screening . 8 . Ocular medication kind within 30 day screen , exception ) ocular hypotensive medication ( must wash accord provided schedule ) , b ) lid scrub ( may use prior , screen ) c ) lubricate drop dry eye ( may use throughout study ) . 9 . Clinically significant ocular disease ( e.g . corneal edema , uveitis , severe keratoconjunctivitis sicca ) might interfere study , include glaucomatous damage severe washout ocular hypotensive medication one month judge safe ( e.g. , cupdisc ratio &gt; 0.8 ) . 10 . Central corneal thickness great 600 µm . 11 . Any abnormality prevent reliable applanation tonometry either eye . Systemic : 12 . Clinically significant abnormality ( determined investigator ) laboratory test screen . 13 . Clinically significant systemic disease ( e.g. , uncontrolled diabetes , myasthenia gravis , hepatic , renal , endocrine cardiovascular disorder ) might interfere study . 14 . Participation investigational study within 30 day prior screen . 15 . Changes systemic medication within 30 day prior screen , anticipate study , could substantial effect IOP . 16 . Women childbearing potential pregnant , nursing , plan pregnancy , use medically acceptable form birth control . An adult woman consider childbearing potential unless one year postmenopausal three month postsurgical sterilization . All female childbearing potential must negative urine pregnancy test result screen examination must intend become pregnant study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Glaucoma</keyword>
	<keyword>Ocular hypertension</keyword>
	<keyword>AR-12286</keyword>
	<keyword>Travoprost</keyword>
</DOC>